<DOC>
	<DOCNO>NCT01652313</DOCNO>
	<brief_summary>The purpose study fulfil regulatory requirement registration new chemical entity China . Rasagiline approve treatment Parkinson 's Disease ( PD ) Europe US . Rasagiline safe well tolerate healthy subject , efficacy safety demonstrate placebo- active comparator-controlled phase III study .</brief_summary>
	<brief_title>Pharmacokinetic Properties Rasagiline ( Lu 00-773 ) Healthy Young Chinese Men Women</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>The subject Chinese man woman The subject , opinion investigator , generally healthy If female , subject must negative pregnancy test screen baseline , agree try become pregnant Screening Followup Visit The subject , opinion investigator , unlikely comply clinical study protocol unsuitable reason . Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>